Loading...
XSHE
002422
Market cap8.49bUSD
Jun 03, Last price  
38.20CNY
1D
-0.93%
1Q
22.28%
Jan 2017
136.97%
IPO
7.00%
Name

Sichuan Kelun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
24.85
P/S
2.85
EPS
1.54
Div Yield, %
2.09%
Shrs. gr., 5y
1.60%
Rev. gr., 5y
5.58%
Revenues
21.45b
+13.44%
2,029,326,5502,621,391,2863,245,985,3454,026,399,9585,147,848,7585,885,278,6176,831,281,9818,023,421,2897,763,339,9828,565,943,41511,434,948,84116,351,790,23917,636,267,04416,464,201,27717,277,407,53318,912,653,46321,453,929,237
Net income
2.46b
+44.03%
216,288,383309,887,206427,851,436661,229,249966,126,0951,087,515,7481,079,521,5861,001,902,613645,271,323584,638,829748,544,1871,212,944,249937,855,128829,386,336868,116,5331,705,324,0672,456,112,045
CFO
5.34b
+70.65%
168,423,194221,075,877250,688,633149,292,039342,931,058402,771,4671,050,373,8451,218,735,9381,239,429,4361,725,407,4151,102,520,8282,953,506,9672,216,737,6392,219,381,5192,847,118,4283,127,457,0905,337,068,931
Dividend
May 29, 20240.8 CNY/sh

Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers IV solutions; injectable powder and small volume parenteral; oral preparation; intermediates and APIs; and peritoneal dialysis solutions. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
URL
https://www.kelun.com/
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
21,453,929
13.44%
18,912,653
9.46%
Cost of revenue
17,070,315
15,751,923
Unusual Expense (Income)
NOPBT
4,383,614
3,160,730
NOPBT Margin
20.43%
16.71%
Operating Taxes
933,787
364,002
Tax Rate
21.30%
11.52%
NOPAT
3,449,827
2,796,728
Net income
2,456,112
44.03%
1,705,324
96.44%
Dividends
(1,126,708)
(597,780)
Dividend yield
2.51%
1.51%
Proceeds from repurchase of equity
13,882
(106,457)
BB yield
-0.03%
0.27%
Debt
Debt current
4,205,128
5,319,441
Long-term debt
3,139,040
4,762,469
Deferred revenue
288,206
208,884
Other long-term liabilities
78
Net debt
(3,593,932)
1,549,149
Cash flow
Cash from operating activities
5,337,069
3,127,457
CAPEX
(1,769,185)
(896,022)
Cash from investing activities
(3,370,325)
(856,590)
Cash from financing activities
(2,058,766)
(407,261)
FCF
1,671,799
2,283,737
Balance
Cash
6,945,956
5,173,412
Long term investments
3,992,143
3,359,350
Excess cash
9,865,403
7,587,129
Stockholders' equity
15,395,221
13,355,120
Invested Capital
20,537,416
19,288,254
ROIC
17.32%
14.70%
ROCE
14.29%
11.65%
EV
Common stock shares outstanding
1,544,725
1,485,828
Price
29.05
9.17%
26.61
40.57%
Market cap
44,874,248
13.50%
39,537,892
47.76%
EV
44,623,532
42,223,771
EBITDA
5,642,373
4,333,232
EV/EBITDA
7.91
9.74
Interest
370,709
473,710
Interest/NOPBT
8.46%
14.99%